Abstract
The relative bioavailability of a 200 mg film-coated tablet of [12C]moricizine·HCI in comparison to a 200 mg [13C6]moricizine·HCI oral solution was determined after simultaneous administration to 8 young healthy male subjects. Concentrations of [12C]moricizine·HCl and [13C6]moricizine·HCI were determined by thermospray liquid chromatography-mass spectrometry (LC-MS) using [2H11]moricizine·HCI as the internal standard. The mean absorption and disposition parameters of the tablet versus the solution were the following (% CV): maximum concentration, 0.83 (39%) versus 0.79 (39%) μg/mL; time of maximum concentration, 0.81 (40%) versus 0.65 (28%) hours; area under the concentration-time curve (AUC), 1.58 (39%) versus 1.49 (37%) μg·h/mL; apparent oral clearance, 150.7 (52%) versus 158.1 (50%) L/h; and t( 1/2 ), 1.9 (42%) versus 1.9 (42%) hours. The AUC for the tablet averaged 106% of the solution, which likely reflects a greater first-pass effect with the oral solution. Partitioning sources of variation confirmed the low (< 6%) intrasubject coefficient of variation (cv) afforded via the single-period, dual-isotope design. In contrast, a previous study using the conventional two-period crossover design determined the cvε about moricizine metrics to be in excess of 30%, resulting in classification of this drug as having highly variable absorption. The results of this studyfurther illustrate the benefits of dual, stable isotopes to assess bioavailability and bioequivalence. This paradigm results in a reduction in experimental time and subject inconvenience and lower costs in comparison with the standard crossover study. Perhaps most important is the improved statistical power for the evaluation of bioavailability or bioequivalence in the absence of period and sequence effects that confound the assessment of intrasubject variation in the standard crossover design. (C)1999 the American College of Clinical Pharmacology.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 817-825 |
| Number of pages | 9 |
| Journal | Journal of Clinical Pharmacology |
| Volume | 39 |
| Issue number | 8 |
| State | Published - 1999 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Moricizine bioavailability via simultaneous, dual, stable isotope administration : Bioequivalence implications. / Pieniaszek H.J., Jr; Mayersohn, Michael; Adams, M. P.; Reinhart, R. J.; Barrett, J. S.
In: Journal of Clinical Pharmacology, Vol. 39, No. 8, 1999, p. 817-825.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Moricizine bioavailability via simultaneous, dual, stable isotope administration
T2 - Bioequivalence implications
AU - Pieniaszek H.J., Jr
AU - Mayersohn, Michael
AU - Adams, M. P.
AU - Reinhart, R. J.
AU - Barrett, J. S.
PY - 1999
Y1 - 1999
N2 - The relative bioavailability of a 200 mg film-coated tablet of [12C]moricizine·HCI in comparison to a 200 mg [13C6]moricizine·HCI oral solution was determined after simultaneous administration to 8 young healthy male subjects. Concentrations of [12C]moricizine·HCl and [13C6]moricizine·HCI were determined by thermospray liquid chromatography-mass spectrometry (LC-MS) using [2H11]moricizine·HCI as the internal standard. The mean absorption and disposition parameters of the tablet versus the solution were the following (% CV): maximum concentration, 0.83 (39%) versus 0.79 (39%) μg/mL; time of maximum concentration, 0.81 (40%) versus 0.65 (28%) hours; area under the concentration-time curve (AUC), 1.58 (39%) versus 1.49 (37%) μg·h/mL; apparent oral clearance, 150.7 (52%) versus 158.1 (50%) L/h; and t( 1/2 ), 1.9 (42%) versus 1.9 (42%) hours. The AUC for the tablet averaged 106% of the solution, which likely reflects a greater first-pass effect with the oral solution. Partitioning sources of variation confirmed the low (< 6%) intrasubject coefficient of variation (cv) afforded via the single-period, dual-isotope design. In contrast, a previous study using the conventional two-period crossover design determined the cvε about moricizine metrics to be in excess of 30%, resulting in classification of this drug as having highly variable absorption. The results of this studyfurther illustrate the benefits of dual, stable isotopes to assess bioavailability and bioequivalence. This paradigm results in a reduction in experimental time and subject inconvenience and lower costs in comparison with the standard crossover study. Perhaps most important is the improved statistical power for the evaluation of bioavailability or bioequivalence in the absence of period and sequence effects that confound the assessment of intrasubject variation in the standard crossover design. (C)1999 the American College of Clinical Pharmacology.
AB - The relative bioavailability of a 200 mg film-coated tablet of [12C]moricizine·HCI in comparison to a 200 mg [13C6]moricizine·HCI oral solution was determined after simultaneous administration to 8 young healthy male subjects. Concentrations of [12C]moricizine·HCl and [13C6]moricizine·HCI were determined by thermospray liquid chromatography-mass spectrometry (LC-MS) using [2H11]moricizine·HCI as the internal standard. The mean absorption and disposition parameters of the tablet versus the solution were the following (% CV): maximum concentration, 0.83 (39%) versus 0.79 (39%) μg/mL; time of maximum concentration, 0.81 (40%) versus 0.65 (28%) hours; area under the concentration-time curve (AUC), 1.58 (39%) versus 1.49 (37%) μg·h/mL; apparent oral clearance, 150.7 (52%) versus 158.1 (50%) L/h; and t( 1/2 ), 1.9 (42%) versus 1.9 (42%) hours. The AUC for the tablet averaged 106% of the solution, which likely reflects a greater first-pass effect with the oral solution. Partitioning sources of variation confirmed the low (< 6%) intrasubject coefficient of variation (cv) afforded via the single-period, dual-isotope design. In contrast, a previous study using the conventional two-period crossover design determined the cvε about moricizine metrics to be in excess of 30%, resulting in classification of this drug as having highly variable absorption. The results of this studyfurther illustrate the benefits of dual, stable isotopes to assess bioavailability and bioequivalence. This paradigm results in a reduction in experimental time and subject inconvenience and lower costs in comparison with the standard crossover study. Perhaps most important is the improved statistical power for the evaluation of bioavailability or bioequivalence in the absence of period and sequence effects that confound the assessment of intrasubject variation in the standard crossover design. (C)1999 the American College of Clinical Pharmacology.
UR - http://www.scopus.com/inward/record.url?scp=0033324606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033324606&partnerID=8YFLogxK
M3 - Article
C2 - 10434234
AN - SCOPUS:0033324606
VL - 39
SP - 817
EP - 825
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
SN - 0091-2700
IS - 8
ER -